#FDA grants accelerated approval to #dostarlimab for stage II–III dMMR/MSI-H rectal cancer.
In AZUR-1, 110/154 patients (71%) needed no further treatment and had no progression at data cutoff.
Organ preservation requires close surveillance; long-term data are pending. #RectalCancer
For details: https://t.co/MqEFEmSwDQ
Dr. @MartinReck2 presents MDT-Bridge at #WCLC26: pts with resectable or borderline resectable NSCLC received 1-2 cycles of durvalumab + chemotherapy then surgery if resectable or CRT if not, followed by adjuvant/consolidation durvalumab. Of those with borderline resectable NSCLC, 62% underwent resection (97% R0). Overall resection rate 75% and 27% pCR rate.
An important step forward in platinum-resistant ovarian cancer. A +4.2-month OS benefit in a PD-L1–selected population is clinically meaningful. Real-world data will be crucial to validate durability and patient selection.
The Immunotherapy Era has officially arrived for Platinum-Resistant Ovarian Cancer!
📢 #FDA Approval (Feb 10, 2026): Pembrolizumab combination now approved based on KEYNOTE-B96.
A huge step forward for PD-L1+ patients
#OvarianCancer#Oncology#Immunotherapy#Keytruda #MedicalOncology
The #FDA has officially approved niraparib + abiraterone for BRCA2-mutated metastatic Hormone-Sensitive Prostate Cancer (#mCSPC).
This approval moves PARP inhibitors to the front line. We are no longer waiting for castration resistance.
The Takeaway: Early Genetic Testing for BRCA2 is now non-negotiable for every metastatic patient at diagnosis.
#ProstateCancer #Oncology #FDAApproval #PrecisionMedicine #Genetics #Urology
A post-hoc analysis of CALGB/SWOG 80702 shows something critical: Celecoxib doesn’t help everyone — only patients with detectable ctDNA after surgery.
We’re finally seeing adjuvant therapy move away from a “treat all” mindset. ctDNA isn’t just prognostic — it’s emerging as a predictive biomarker that tells us who truly benefits from therapy and who doesn’t need additional toxicity or cost.
#Oncology #ColorectalCancer #ctDNA #PrecisionMedicine #JAMAOncology #CancerResearch #Biomarkers #AdjuvantTherapy #MedicalScience #ClinicianInsight
New Evidence on ADT Duration in Prostate Cancer (JAMA Oncology, Nov 2025)
A meta-analysis of 10,266 patients shows a clear message.
Risk-based approach matters:
• 1 intermediate risk factor → 0 months
• ≥2 risk factors → ~6 months
• High-risk → ~12 months
• Very high-risk → individualize
This study challenges the old “longer is better” dogma and supports personalized ADT duration rather than fixed timelines.
🔗 https://t.co/Exlljkt77x
MATTERHORN #ESMO25 – LBA81
Durvalumab + FLOT becomes the first peri-operative immunotherapy regimen to show an overall survival benefit in resectable gastric/GEJ cancer.
Viewed alongside the #ASCO25 interim (EFS, pCR) results, the final OS data complete the picture — consolidating Durvalumab + FLOT as a potential new standard of care.
#MATTERHORN #Durvalumab #FLOT #GastricCancer #Immunotherapy #Oncology #ClinicalTrials
@CParkMD@tugbawitter@Dr_ElvinaA @atakansare2016 @drmukremin@dr_yakupergun
❗️In oncology, we celebrate treatment breakthroughs…
Yet patients still ask: “Will a biopsy spread my cancer?”
This myth delays care.
Where did the 'Biopsy spreads cancer' myth come from? Facts vs. Fear.
🚀 Precision oncology keeps pushing boundaries.
As of 2025, no new tissue-agnostic FDA approvals yet —
…but several promising candidates are on the horizon:
🧪 CLDN18.2
🧬 FGFR fusions
🔁 KRAS G12C (pan-cancer trials underway)
📊 Explore what’s approved & where the field is heading ⤵️
#Oncology #TissueAgnostic #CancerResearch #FDA #TargetedTherapy
👉 FDA approves SIR-Spheres Y-90 Resin as the first radioembolization therapy with dual indication for:
• Unresectable HCC
• Colorectal liver mets
📊 In the phase II DOORwaY-90 trial (n=134):
✅ 99.5% BORR
✅ 100% local control
📈 >300 days median response
👇Compare with systemic OS outcomes.
For details: https://t.co/Cx2LNUO8Gk
#HCC #LiverCancer #Y90 #FDAapproval #FDA @US_FDA@SirtexMedical
🚨 Exercise is no longer optional, it is essential!
One of the most impactful studies at #ASCO25
🏃♂️ The #CHALLENGE trial (LBA4319) proves that structured exercise after chemo in stage III colon cancer is not just lifestyle—it’s life-saving.
📊 5y DFS: 80.3% vs 73.9%
❤️ 8y OS: 90.3% vs 83.2%
📉 Mortality risk ↓ by 37%
📄 Simultaneously in @NEJM https://t.co/y4e9u71OLI
#ColorectalCancer #OncoTwitter #ExerciseOncology #exercise
💥 Pembrolizumab sets new benchmark in unresectable head & neck cancer: median EFS hits 71.8 months vs 49.8 with CRT alone! #ASCO25#KEYNOTE412#HNSCC#Immunotherapy
Congrats to @ErikaHamilton9 for presenting the VERITAC-2 trial!
📈 In ESR1-mutant breast cancer, vepdegestrant doubled PFS vs fulvestrant (5.0 vs 2.1 mo) and achieved ORR: 18.6% vs 4.0%
🧪 Published in @NEJM 🔗 https://t.co/Uexr7uFAPJ
#ASCO25#BreastCancer#Oncology
🚨 Game-changer at #ASCO25 : The BREAKWATER trial, published simultaneously in #NEJM, shows that EC + mFOLFOX6 doubles overall survival in BRAF V600E-mutant metastatic colorectal cancer vs. standard chemo.
🧬 OS: 30.3 vs. 15.1 mo | ORR: 63.7% vs. 23.5%
📈 A new 1st-line standard in sight? #Oncology #CRC
✅ A global look at first-line EGFR TKI approvals in EGFR-mutant NSCLC!
📍 According to the 2025 ASCO Educational Book, the treatment landscape for EGFR+ non–small cell lung cancer has evolved significantly from 2009 to 2024.
📈 The timeline below highlights key milestones in the approval of EGFR TKIs across the US 🇺🇸, EU 🇪🇺, and China 🇨🇳.
☀️ In 2024, two major regimens have emerged for high-risk patients:
* Osimertinib + platinum-based chemotherapy
* Amivantamab + Lazertinib
🧠 Importantly, there are subpopulations of patients who may benefit more from combination therapy — particularly those with:
* TP53 co-mutations
* High tumor burden
* Brain metastases
* Detectable ctDNA
⚠️ However, increased toxicity demands careful patient selection and shared decision-making. Quality of life matters.
📖 Read more in:
"Navigating First-Line Treatment Options for Patients With EGFR+ NSCLC"
ASCO Educational Book, 2025
🔗 https://t.co/vuqlnWKecw
#ASCO25 #EGFR #LungCancer #NSCLC #TargetedTherapy #PrecisionMedicine